Tetraphase Pharmaceuticals announces IPO pricing
Tetraphase Pharmaceuticals Inc. announced Wednesday the pricing of its initial public offering of 10,714,286 shares of common stock at a price to the public of $7.00 per share, less underwriting discounts and commissions.
Watertown-based Tetraphase said in a press release that its common stock is expected to begin trading on the NASDAQ Global Market under the symbol “TTPH” on March 20.
Tetraphase has granted the underwriters a 30-day option to purchase up to 1,607,143 additional shares of common stock at the same price to cover over allotments, if any.
Barclays and BMO Capital Markets are acting as joint book-running managers. Stifel, JMP Securities, and Needham & Company are acting as co-managers for the offering.
Tetraphase is a clinical-stage biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening multi-drug resistant infections.
MOST E-MAILED »
- Tornado warning issued for southwestern Mass.
- Soldiers flood western Mexico to protect towns
- Coursera to offer new MOOC options for teachers
- Menotomy Grill & Tavern looking to open in Arlington after Memorial Day
- What does the receivers depth chart look like?
- Harvard students demand inquiry into immigration thesis
- Fresh brewed iced coffee from 1369, delivered by bike to your door
